Ozempic Gastroparesis Attorney: Statute of Limitations for Ozempic in Michigan

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Emerging Pharmaceutical Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy heritage emphasized broad awareness of wellness principles and the importance of informed decision-making in healthcare. Within this context, the public has been educated about common medications, their intended benefits, and the general framework of patient safety. As scientific knowledge evolves, so too does the need to address emerging concerns that arise from widespread pharmaceutical use. One such area of growing attention involves medications originally developed for chronic metabolic conditions, which have since seen expanded use across diverse patient populations. This shift in prescribing patterns introduces new considerations for long-term health outcomes, particularly when adverse effects become apparent only after extended exposure. In the occupational setting, professionals who regularly handle or administer these medications may face unique exposure risks that differ from those of the general patient population. The transition from general health education to a focused occupational concern requires careful examination of how routine contact with such substances could influence health trajectories. For instance, the medication Ozempic has been associated with reports of gastroparesis, prompting legal inquiries into liability and timelines for action. In Michigan, understanding the statute of limitations for filing claims related to Ozempic-induced gastroparesis becomes a critical occupational health consideration for affected workers.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which contributes to glycemic control but also underlies a spectrum of gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, abdominal pain, and early satiety. Clinical presentation of gastroparesis often includes chronic nausea and vomiting, postprandial fullness, and abdominal discomfort, which can be debilitating and lead to nutritional deficiencies, weight loss, and reduced quality of life. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules to confirm delayed emptying. Evidence from clinical trials demonstrates a clear dose-dependent increase in gastrointestinal adverse reactions among Ozempic users. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients include nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, gastrointestinal adverse reactions with a frequency of <5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (placebo 0%, Ozempic 0.5 mg 2.7%, Ozempic 1 mg 1.1%), flatulence (placebo 0.8%, Ozempic 0.5 mg 0.4%, Ozempic 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, Ozempic 0.5 mg 1.9%, Ozempic 1 mg 1.5%), and gastritis (placebo 0.8%, Ozempic 0.5 mg 0.8%, Ozempic 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The mechanistic pathway linking Ozempic to gastroparesis is rooted in its GLP-1 receptor agonist activity, which delays gastric emptying as a therapeutic effect. However, in susceptible individuals, this delay can become pathological, leading to gastroparesis. The drug's labeling acknowledges gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct adverse event. This raises questions about the adequacy of warnings, as patients and healthcare providers may not associate chronic, severe gastrointestinal symptoms with Ozempic use, potentially delaying diagnosis and treatment.

Legal Implications for Michigan Patients: Statute of Limitations

For affected patients in Michigan, attorney-related considerations are critical. The statute of limitations for product liability claims in Michigan is generally three years from the date of injury or from when the injury was discovered or should have been discovered. Given the timeline between exposure to Ozempic and documented harm, patients who developed gastroparesis after starting Ozempic must act promptly. The onset of symptoms often occurs during dose escalation, as noted in clinical trials, but chronic gastroparesis may develop over months. Patients should document the start date of Ozempic use, the onset of gastrointestinal symptoms, and any medical diagnoses of gastroparesis. This timeline is essential for legal claims, as it establishes the link between exposure and harm. In summary, Ozempic use is associated with a high incidence of gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which can progress to gastroparesis. The drug's labeling does not explicitly warn of gastroparesis, potentially leaving patients unaware of the risk. Michigan patients who have developed gastroparesis after using Ozempic should consult an attorney to evaluate their claims within the statute of limitations. Evidence from clinical trials underscores the dose-dependent nature of these adverse effects, supporting the plausibility of a causal link. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Michigan?

In Michigan, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, this means patients must file within three years of the onset of symptoms or diagnosis, whichever is later. It is crucial to consult an attorney promptly to ensure your claim is filed within the legal timeframe.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its therapeutic effect. In susceptible individuals, this delay can become pathological, leading to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. Clinical trials show a dose-dependent increase in gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which can progress to gastroparesis. The drug's labeling does not explicitly warn of gastroparesis, potentially delaying diagnosis. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.